Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Industry experts predicts tough choices as NewJeans' ultimatum nears

    Industry experts predicts tough choices as NewJeans' ultimatum nears
  2. 2

    Jung's paternity reveal exposes where Korea stands on extramarital babies

    Jung's paternity reveal exposes where Korea stands on extramarital babies
  3. 3

    Seoul city opens emergency care centers

    Seoul city opens emergency care centers
  4. 4

    Opposition chief acquitted of instigating perjury

    Opposition chief acquitted of instigating perjury
  5. 5

    [Exclusive] Hyundai Mobis eyes closer ties with BYD

    [Exclusive] Hyundai Mobis eyes closer ties with BYD
  1. 6

    [Herald Review] 'Gangnam B-Side' combines social realism with masterful suspense, performance

    [Herald Review] 'Gangnam B-Side' combines social realism with masterful suspense, performance
  2. 7

    Why S. Korean refiners are reluctant to import US oil despite Trump’s energy push

    Why S. Korean refiners are reluctant to import US oil despite Trump’s energy push
  3. 8

    Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations

    Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations
  4. 9

    Prosecutors seek 5-year prison term for Samsung chief in merger retrial

    Prosecutors seek 5-year prison term for Samsung chief in merger retrial
  5. 10

    UN talks on plastic pollution treaty begin with grim outlook

    UN talks on plastic pollution treaty begin with grim outlook
지나쌤

Samsung Biologics, AstraZeneca shutting down their joint venture Archigen Biotech

By Yonhap

Published : May 24, 2022 - 10:25

    • Link copied

This image provided by Samsung Biologics Co. shows the company's pharmaceutical production plant. (Yonhap) This image provided by Samsung Biologics Co. shows the company's pharmaceutical production plant. (Yonhap)

Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, is shutting down its joint venture with multinational pharmaceutical company AstraZeneca Plc., a company official said Tuesday, due to the suspension of the development of a biosimilar product.

The move came two months after Samsung Biologics' board approved the liquidation of Archigen Biotech Ltd., a 50-50 joint venture set up with AstraZeneca, in 2014.

Archigen Biotech was responsible for developing SAIT101, a biosimilar of Rituximab, which is used for the treatment of lymphoma. A biosimilar is a very similar copy of an already approved reference biologic drug.

But Samsung Biologics and AstraZeneca reportedly decided to halt the project in the second half of 2020 as competitors, such as Celltrion Inc., have begun selling similar products. (Yonhap)

More from Headlines